HC Wainwright reaffirmed their buy rating on shares of Cytosorbents (NASDAQ:CTSO) in a research report sent to investors on Tuesday. HC Wainwright currently has a $14.00 price target on the medical research company’s stock.
A number of other brokerages have also recently issued reports on CTSO. B. Riley set a $11.00 target price on Cytosorbents and gave the stock a buy rating in a report on Friday, December 22nd. ValuEngine upgraded Cytosorbents from a sell rating to a hold rating in a report on Tuesday. Finally, Maxim Group set a $12.00 target price on Cytosorbents and gave the stock a buy rating in a report on Thursday, December 21st. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $10.60.
Shares of Cytosorbents (NASDAQ CTSO) traded up $0.20 on Tuesday, hitting $7.80. The company had a trading volume of 176,874 shares, compared to its average volume of 132,709. Cytosorbents has a 12 month low of $3.30 and a 12 month high of $7.85. The company has a current ratio of 3.36, a quick ratio of 3.17 and a debt-to-equity ratio of 0.73. The company has a market cap of $223.79, a PE ratio of -20.53 and a beta of -0.54.
A number of large investors have recently modified their holdings of CTSO. Wealthcare Advisory Partners LLC bought a new position in Cytosorbents during the 3rd quarter valued at $365,000. PNC Financial Services Group Inc. lifted its stake in Cytosorbents by 145.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 38,000 shares of the medical research company’s stock valued at $163,000 after acquiring an additional 22,500 shares in the last quarter. Finally, Fortaleza Asset Management Inc. lifted its stake in Cytosorbents by 81.6% during the 3rd quarter. Fortaleza Asset Management Inc. now owns 23,375 shares of the medical research company’s stock valued at $145,000 after acquiring an additional 10,500 shares in the last quarter. Institutional investors and hedge funds own 8.65% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Cytosorbents’ (CTSO) “Buy” Rating Reaffirmed at HC Wainwright” was published by Community Financial News and is owned by of Community Financial News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.com-unik.info/2018/01/12/cytosorbents-ctso-buy-rating-reaffirmed-at-hc-wainwright.html.
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.